A Phase 1 Study Investigating Survival of HP802-247 Allogenic Cells in Excisional Acute Cutaneous Wounds

StatusFinished
Effective start/end date1/09/1031/12/10

Funding

  • Healthpoint, Ltd.: $18,853.00

Keywords

  • Biotechnology & Drug Development, Genomics, Investigative Genetics